Pars plana vitrectomy followed by subretinal or intravitreal injection with Conbercept and tissue plasminogen activator for clearance of submacular hemorrhage secondary to idiopathic polypoidal choroidal vasculopathy.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

International Ophthalmology Pub Date : 2025-08-30 DOI:10.1007/s10792-025-03642-y

Fan Yang, Lumei Luo, Yusheng Li, Lingyao Wu, Qi Wan, Wenghan Ji, Zhipeng You

{"title":"Pars plana vitrectomy followed by subretinal or intravitreal injection with Conbercept and tissue plasminogen activator for clearance of submacular hemorrhage secondary to idiopathic polypoidal choroidal vasculopathy.","authors":"Fan Yang, Lumei Luo, Yusheng Li, Lingyao Wu, Qi Wan, Wenghan Ji, Zhipeng You","doi":"10.1007/s10792-025-03642-y","DOIUrl":null,"url":null,"abstract":"Purpose: The optimal treatment approach for submacular hemorrhage (SMH) secondary to idiopathic polypoid choroidal vasculopathy (IPCV) remains uncertain. This study aimed to explore the prognosis and complications of pars plana vitrectomy (PPV) followed by subretinal or intravitreal injection with Conbercept (0.05 ml, 10 mg/ml) and tissue plasminogen activator (t-PA) (0.05 ml ~ 0.1 ml, 0.25 mg/ml) for submacular hemorrhage (SMH) secondary to IPCV.Methods: This retrospective study included patients with SMH secondary to IPCV who received PPV followed by subretinal or intravitreal injection with Conbercept and t-PA at the Affiliated Eye Hospital of Nanchang University between March and November 2023. The rate of SMH clearance, best corrected visual acuity (BCVA), and central macular thickness (CMT), and postoperative complications at 1 week, 1 month, 3 months and 6 months post-treatment were collected.Results: A total of 41 patients were included, with 22 (8 males, 14 left eyes) of who received subretinal injection.Patients who received subretinal injection showed significantly less times of injections (P = 0.008), compared with those received intravitreal injection. Repeated measurement analysis showed that, compared with intravitreal injection, patients who received subretinal injection exhibited significant higher SMH clearance ratio (P < 0.001), while comparable BCVA (P = 0.942) and CMT (0.906). In addition, the occurrence of postoperative complications, including vitreous hemorrhage (P = 0.999) and macular hemorrhage (P = 0.463), between those received subretinal and intravitreal injection were similar.Conclusion: Compared with intravitreal injection, PPV followed by subretinal injection with Conbercept and t-PA might be a more optimal protocol with higher SMH clearance ratio for SMH Secondary to IPCV.","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":"45 1","pages":"364"},"PeriodicalIF":1.4000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-025-03642-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The optimal treatment approach for submacular hemorrhage (SMH) secondary to idiopathic polypoid choroidal vasculopathy (IPCV) remains uncertain. This study aimed to explore the prognosis and complications of pars plana vitrectomy (PPV) followed by subretinal or intravitreal injection with Conbercept (0.05 ml, 10 mg/ml) and tissue plasminogen activator (t-PA) (0.05 ml ~ 0.1 ml, 0.25 mg/ml) for submacular hemorrhage (SMH) secondary to IPCV.

Methods: This retrospective study included patients with SMH secondary to IPCV who received PPV followed by subretinal or intravitreal injection with Conbercept and t-PA at the Affiliated Eye Hospital of Nanchang University between March and November 2023. The rate of SMH clearance, best corrected visual acuity (BCVA), and central macular thickness (CMT), and postoperative complications at 1 week, 1 month, 3 months and 6 months post-treatment were collected.

Results: A total of 41 patients were included, with 22 (8 males, 14 left eyes) of who received subretinal injection.Patients who received subretinal injection showed significantly less times of injections (P = 0.008), compared with those received intravitreal injection. Repeated measurement analysis showed that, compared with intravitreal injection, patients who received subretinal injection exhibited significant higher SMH clearance ratio (P < 0.001), while comparable BCVA (P = 0.942) and CMT (0.906). In addition, the occurrence of postoperative complications, including vitreous hemorrhage (P = 0.999) and macular hemorrhage (P = 0.463), between those received subretinal and intravitreal injection were similar.

Conclusion: Compared with intravitreal injection, PPV followed by subretinal injection with Conbercept and t-PA might be a more optimal protocol with higher SMH clearance ratio for SMH Secondary to IPCV.

查看原文本刊更多论文

玻璃体切除后视网膜下或玻璃体内注射Conbercept和组织纤溶酶原激活剂用于清除特发性息肉样脉络膜血管病变继发的黄斑下出血。

目的：特发性息肉样脉络膜血管病变（IPCV）继发的黄斑下出血（SMH）的最佳治疗方法仍不确定。本研究旨在探讨玻璃体切割（PPV）术后视网膜下或玻璃体内注射Conbercept （0.05 ml, 10 mg/ml）和组织型纤溶酶原激活剂（t-PA）（0.05 ml ~ 0.1 ml, 0.25 mg/ml）治疗IPCV继发性黄斑下出血（SMH）的预后及并发症。方法：本回顾性研究纳入了南昌大学附属眼科医院于2023年3月至11月期间接受PPV后视网膜下或玻璃体内注射Conbercept和t-PA的继发性IPCV SMH患者。观察治疗后1周、1个月、3个月、6个月的SMH清除率、最佳矫正视力（BCVA）、中央黄斑厚度（CMT）及术后并发症。结果：共纳入41例患者，其中22例（男8例，左眼14例）行视网膜下注射。与玻璃体内注射组相比，视网膜下注射组的注射次数明显减少（P = 0.008）。反复测量分析显示，与玻璃体内注射相比，接受视网膜下注射的患者SMH清除率明显更高(P)。结论：与玻璃体内注射相比，PPV后视网膜下注射Conbercept和t-PA可能是治疗IPCV继发性SMH的更优方案，SMH清除率更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

451

期刊介绍： International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.